311 related articles for article (PubMed ID: 28550264)
1. Depressive Symptoms are Associated with Progression to Dementia in Patients with Amyloid-Positive Mild Cognitive Impairment.
Moon B; Kim S; Park YH; Lim JS; Youn YC; Kim S; Jang JW;
J Alzheimers Dis; 2017; 58(4):1255-1264. PubMed ID: 28550264
[TBL] [Abstract][Full Text] [Related]
2. Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study.
Wu KY; Liu CY; Chen CS; Chen CH; Hsiao IT; Hsieh CJ; Lee CP; Yen TC; Lin KJ
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1067-76. PubMed ID: 26739329
[TBL] [Abstract][Full Text] [Related]
3. Cortical Amyloid β Deposition and Current Depressive Symptoms in Alzheimer Disease and Mild Cognitive Impairment.
Chung JK; Plitman E; Nakajima S; Chakravarty MM; Caravaggio F; Gerretsen P; Iwata Y; Graff-Guerrero A;
J Geriatr Psychiatry Neurol; 2016 May; 29(3):149-59. PubMed ID: 26400248
[TBL] [Abstract][Full Text] [Related]
4. Chronic Depressive Symptomatology in Mild Cognitive Impairment Is Associated with Frontal Atrophy Rate which Hastens Conversion to Alzheimer Dementia.
Sacuiu S; Insel PS; Mueller S; Tosun D; Mattsson N; Jack CR; DeCarli C; Petersen R; Aisen PS; Weiner MW; Mackin RS;
Am J Geriatr Psychiatry; 2016 Feb; 24(2):126-35. PubMed ID: 26238228
[TBL] [Abstract][Full Text] [Related]
5. Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment.
Ten Kate M; Barkhof F; Visser PJ; Teunissen CE; Scheltens P; van der Flier WM; Tijms BM
Alzheimers Res Ther; 2017 Sep; 9(1):73. PubMed ID: 28899429
[TBL] [Abstract][Full Text] [Related]
6. Depressive Symptoms and Small Hippocampal Volume Accelerate the Progression to Dementia from Mild Cognitive Impairment.
Chung JK; Plitman E; Nakajima S; Chakravarty MM; Caravaggio F; Takeuchi H; Gerretsen P; Iwata Y; Patel R; Mulsant BH; Graff-Guerrero A
J Alzheimers Dis; 2016; 49(3):743-54. PubMed ID: 26519442
[TBL] [Abstract][Full Text] [Related]
7. Posterior atrophy predicts time to dementia in patients with amyloid-positive mild cognitive impairment.
Pyun JM; Park YH; Kim HR; Suh J; Kang MJ; Kim BJ; Youn YC; Jang JW; Kim S;
Alzheimers Res Ther; 2017 Dec; 9(1):99. PubMed ID: 29246250
[TBL] [Abstract][Full Text] [Related]
8. Left lateralized cerebral glucose metabolism declines in amyloid-β positive persons with mild cognitive impairment.
Weise CM; Chen K; Chen Y; Kuang X; Savage CR; Reiman EM;
Neuroimage Clin; 2018; 20():286-296. PubMed ID: 30101060
[TBL] [Abstract][Full Text] [Related]
9. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
10. Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia.
Yew B; Nation DA;
Brain; 2017 Jul; 140(7):1987-2001. PubMed ID: 28575149
[TBL] [Abstract][Full Text] [Related]
11. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
[TBL] [Abstract][Full Text] [Related]
12. The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.
Niemantsverdriet E; Ottoy J; Somers C; De Roeck E; Struyfs H; Soetewey F; Verhaeghe J; Van den Bossche T; Van Mossevelde S; Goeman J; De Deyn PP; Mariën P; Versijpt J; Sleegers K; Van Broeckhoven C; Wyffels L; Albert A; Ceyssens S; Stroobants S; Staelens S; Bjerke M; Engelborghs S
J Alzheimers Dis; 2017; 60(2):561-576. PubMed ID: 28869470
[TBL] [Abstract][Full Text] [Related]
13. Association of brain amyloidosis with the incidence and frequency of neuropsychiatric symptoms in ADNI: a multisite observational cohort study.
Goukasian N; Hwang KS; Romero T; Grotts J; Do TM; Groh JR; Bateman DR; Apostolova LG
BMJ Open; 2019 Dec; 9(12):e031947. PubMed ID: 31857304
[TBL] [Abstract][Full Text] [Related]
14. Amyloid-β deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression.
Huijbers W; Mormino EC; Schultz AP; Wigman S; Ward AM; Larvie M; Amariglio RE; Marshall GA; Rentz DM; Johnson KA; Sperling RA
Brain; 2015 Apr; 138(Pt 4):1023-35. PubMed ID: 25678559
[TBL] [Abstract][Full Text] [Related]
15. Serotonin Selective Reuptake Inhibitor Treatment Improves Cognition and Grey Matter Atrophy but not Amyloid Burden During Two-Year Follow-Up in Mild Cognitive Impairment and Alzheimer's Disease Patients with Depressive Symptoms.
Brendel M; Sauerbeck J; Greven S; Kotz S; Scheiwein F; Blautzik J; Delker A; Pogarell O; Ishii K; Bartenstein P; Rominger A;
J Alzheimers Dis; 2018; 65(3):793-806. PubMed ID: 30010116
[TBL] [Abstract][Full Text] [Related]
16. A 'Comprehensive Visual Rating Scale' for predicting progression to dementia in patients with mild cognitive impairment.
Jang JW; Park JH; Kim S; Park YH; Pyun JM; Lim JS; Kim Y; Youn YC; Kim S;
PLoS One; 2018; 13(8):e0201852. PubMed ID: 30125290
[TBL] [Abstract][Full Text] [Related]
17. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
[TBL] [Abstract][Full Text] [Related]
18. Added value and limitations of amyloid-PET imaging: review and analysis of selected cases of mild cognitive impairment and dementia.
Weidman DA; Zamrini E; Sabbagh MN; Jacobson S; Burke A; Belden C; Powell J; Bhalla N; Roontiva A; Kuang X; Luo J; Chen K; Riggs G; Burke W
Neurocase; 2017 Feb; 23(1):41-51. PubMed ID: 28376695
[TBL] [Abstract][Full Text] [Related]
19. Urine AD7c-NTP Predicts Amyloid Deposition and Symptom of Agitation in Patients with Alzheimer's Disease and Mild Cognitive Impairment.
Zhang N; Zhang L; Li Y; Gordon ML; Cai L; Wang Y; Xing M; Cheng Y
J Alzheimers Dis; 2017; 60(1):87-95. PubMed ID: 28777752
[TBL] [Abstract][Full Text] [Related]
20. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
